Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Benzinga · 2d ago
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.